Research programme: inositol trisphosphate receptor antagonists - Nxera Pharma/Tokyo University
Alternative Names: Research programme: IP3 receptor antagonists - Nxera Pharma/Tokyo UniversityLatest Information Update: 02 Apr 2024
At a glance
- Originator Sosei; University of Tokyo
- Developer Nxera Pharma; University of Tokyo
- Class
- Mechanism of Action Inositol 1,4,5 trisphosphate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis; Atopic dermatitis